HC Wainwright Expects Reduced Earnings for Zenas BioPharma

Zenas BioPharma, Inc. (NASDAQ:ZBIO) – Analysts at HC Wainwright lowered their FY2026 EPS estimates for shares of Zenas BioPharma in a report released on Monday, November 9th. HC Wainwright analyst M. Caufield now expects that the company will earn ($6.26) per share for the year, down from their previous estimate of ($5.83). HC Wainwright currently has a “Buy” rating and a $44.00 target price on the stock. The consensus estimate for Zenas BioPharma’s current full-year earnings is ($6.09) per share. HC Wainwright also issued estimates for Zenas BioPharma’s Q4 2026 earnings at ($1.39) EPS, FY2027 earnings at ($5.10) EPS, FY2028 earnings at ($3.41) EPS, FY2029 earnings at ($2.42) EPS and FY2030 earnings at ($1.10) EPS.

ZBIO has been the topic of several other research reports. Citigroup restated a “buy” rating on shares of Zenas BioPharma in a report on Wednesday, October 28th. Guggenheim reaffirmed a “buy” rating and set a $55.00 price objective on shares of Zenas BioPharma in a research note on Wednesday, September 30th. Wedbush reaffirmed an “outperform” rating and set a $45.00 price objective on shares of Zenas BioPharma in a research note on Wednesday, September 30th. Morgan Stanley initiated coverage on shares of Zenas BioPharma in a research report on Tuesday, October 20th. They set an “equal weight” rating and a $32.00 price objective on the stock. Finally, Weiss Ratings downgraded shares of Zenas BioPharma from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, November 4th. Six investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $46.71.

Zenas BioPharma Trading Up 0.0%

Shares of ZBIO stock opened at $28.58 on Wednesday. The company has a market cap of $1.86 billion, a PE ratio of -3.03 and a beta of -0.88. Zenas BioPharma has a 1 year low of $13.50 and a 1 year high of $44.60. The stock’s 50 day simple moving average is $28.85 and its two-hundred day simple moving average is $25.22. The company has a debt-to-equity ratio of 1.88, a current ratio of 9.42 and a quick ratio of 9.93.

Zenas BioPharma (NASDAQ:ZBIO) last released its quarterly earnings results on Thursday, November 5th. The company reported ($1.65) EPS for the quarter, missing the consensus estimate of ($1.24) by ($0.41). The company had revenue of $10.00 million during the quarter, compared to the consensus estimate of $10.00 million.

Institutional Investors Weigh In On Zenas BioPharma

Hedge funds and other institutional investors have recently modified their holdings of the business. Sterling Capital Management LLC boosted its holdings in Zenas BioPharma by 1,090.0% during the 3rd quarter. Sterling Capital Management LLC now owns 1,190 shares of the company’s stock valued at $32,000 after acquiring an additional 1,090 shares during the period. Quantbot Technologies LP bought a new stake in shares of Zenas BioPharma during the second quarter worth $49,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in shares of Zenas BioPharma during the third quarter worth $90,000. Jupiter Topco LLC purchased a new stake in shares of Zenas BioPharma during the second quarter valued at $201,000. Finally, The Manufacturers Life Insurance Company purchased a new stake in shares of Zenas BioPharma during the second quarter valued at $204,000.

About Zenas BioPharma

Zenas BioPharma is a clinical-stage biopharmaceutical company focused on developing treatments for autoimmune diseases. Founded in 2019 and based in Waltham, Massachusetts, the company describes itself as a global biopharmaceutical business. Its lead investigational medicine, obexelimab, is a bifunctional antibody designed to bind CD19 and FcγRIIb and inhibit B-cell activity. Zenas is developing the drug for autoimmune conditions, including IgG4-related disease; it has not been approved for commercial use.